Funded, Aug 1, 2016
BRAF V600 mutation-positive unresectable or metastatic melanoma.
• Previously untreated or as second line treatment for patients previously treated with first line pembrolizumab or ipilimumab or nivolumab or combination.
• Only one BRAF/MEK targeted treatment will be funded (daBRAFenib, trametinib, or combination).
• ECOG 0 to 1.
• Adequate hematological, hepatic and renal function.
• If brain metastases are present, patients should be asymptomatic or stable.

Funded, Oct 18, 2016
Criteria update Oct. 30, 2018: Dabrafenib and/or trametinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Not to be used after progression on an alternate BRAF inhibitor and/or MEK inhibitor.

Funded, Aug 8, 2016
First line BRAF targeted therapy (i.e. patients may be treatment naïve or previously treated with checkpoint inhibitor immunotherapy and/or chemotherapy) with the combination of Dabrafenib and Trametinib in patients with BRAF V600 mutation positive unresectable or metastatic melanoma who have an ECOG performance status of 0 or 1 and stable brain metastases (if present).

Funded, Jul 21, 2016
For the treatment of Unresectable or Metastatic Melanoma when used in combination with Tafinlar (dabrafenib).

Funded, Aug 10, 2016
Initial requests: As a first line treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma; OR as a second line treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma in which the disease has progressed after receiving treatment in the first line setting. If brain metastases are present, they should be asymptomatic or stable. Exclusion criteria: BRAF V600 negative, or wild type tumours, or unknown status will not be funded. o Dabrafenibtrametinib combination therapy will not be considered for funding in patients who have progressed on a prior BRAF inhibitor therapy.

Funded, Sept 1, 2016
Tafinlar Mekinist combination therapy as a firstline BRAF-mutation targeted treatment for patients with BRAF V600 mutation positive, unresectable or metastatic melanoma and who have an ECOG performance status of 0 or 1.
Treatment should continue until disease progression. If brain metastases are present, patients should be asymptomatic or have stable symptoms.

Funded, Mar 13, 2017
For the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, when used as first line therapy, alone or in combination with trametinib.

Funded, Feb 1, 2017
First-line BRAF-mutation targeted treatment (i.e. patients may be treatment naïve or previously treated with checkpoint inhibitor immunotherapy and/or chemotherapy) with Tafinlar Mekinist (Dabrafenib Trametinib) combination therapy for patients with BRAF V600 mutation positive, unresectable or metastatic melanoma and who
have an ECOG performance status of 0 or 1. If brain metastases are present, patients should be asymptomatic or have stable symptoms. Treatment should continue until disease progression.

Funded, Oct 29, 2018
Melanoma – Advanced (Unresctable or Metastatic) -For the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma when used alone or in combination with trametinib. Clinical Notes:
1. Patients must have an ECOG performance status of 0 or 1.
2. If brain metastases are present, patients should be asymptomatic or have stable symptoms.
3. Treatment should be discontinued upon disease progression or unacceptable toxicity.
Patients must apply for coverage under the High-Cost Drug Program. If written by an oncologist, this medication does not require the submission of a Pharmacare Special Authorization form